Medicine and Dentistry
Patient
100%
Therapeutic Procedure
79%
Glioblastoma
57%
Survival
42%
Neoplasm
33%
Ganglioglioma
28%
Chemotherapy
28%
Malignant Neoplasm
27%
Incidence
26%
Intracranial Tumor
26%
Age
23%
Analysis
21%
Temozolomide
17%
Overall Survival
16%
Surgery
15%
Clinical Trial
15%
Diagnosis
14%
Central Nervous System
13%
Bevacizumab
13%
Adverse Event
13%
Oncology
13%
Quality of Life
13%
Lung Cancer
12%
Radiation Therapy
12%
Neuro-Oncology
11%
Cancer Treatment
11%
Evaluation
10%
Pediatrics
10%
Physician
10%
Diseases
10%
Cohort Effect
10%
Descriptive Epidemiology
9%
Histology
9%
Meningioma
9%
Progression Free Survival
8%
Cancer Registry
8%
Brain Metastasis
8%
Non Small Cell Lung Cancer
8%
Brain
7%
Randomized Clinical Trial
7%
Psychogenic Non-Epileptic Seizures
7%
Germinoma
7%
Identity
7%
Phase II Trials
7%
Squamous Cell Carcinoma
7%
Immunotherapy
7%
Male
7%
Surveillance, Epidemiology, and End Results
7%
Association
6%
Tumor Treating Fields
6%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
46%
Neoplasm
40%
Malignant Neoplasm
32%
Temozolomide
28%
Survival
28%
Incidence
21%
Epidemiology
20%
Adverse Event
19%
Bevacizumab
16%
Glioma
15%
Overall Survival
14%
Chemotherapy
13%
Intracranial Tumor
12%
Disease
10%
Brain Metastasis
10%
Clinical Trial
10%
Phase II Trials
9%
Irinotecan
9%
Toxicity
8%
Progression Free Survival
8%
Non Small Cell Lung Cancer
7%
Randomized Clinical Trial
7%
Immunotherapy
7%
Psychogenic Nonepileptic Seizure
7%
Germ Cell Tumor
7%
Meningioma
6%
Central Nervous System Tumor
6%
Seizure
5%
Cancer Incidence
5%
Survival Rate
5%
Astrocytoma
5%